300 related articles for article (PubMed ID: 30115703)
21. Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML.
Duy C; Teater M; Garrett-Bakelman FE; Lee TC; Meydan C; Glass JL; Li M; Hellmuth JC; Mohammad HP; Smitheman KN; Shih AH; Abdel-Wahab O; Tallman MS; Guzman ML; Muench D; Grimes HL; Roboz GJ; Kruger RG; Creasy CL; Paietta EM; Levine RL; Carroll M; Melnick AM
Cancer Discov; 2019 Jul; 9(7):872-889. PubMed ID: 31076479
[TBL] [Abstract][Full Text] [Related]
22. Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia.
Hayashi Y; Goyama S; Liu X; Tamura M; Asada S; Tanaka Y; Fukuyama T; Wunderlich M; O'Brien E; Mizukawa B; Yamazaki S; Matsumoto A; Yamasaki S; Shibata T; Matsuda K; Sashida G; Takizawa H; Kitamura T
Nat Commun; 2019 Oct; 10(1):4869. PubMed ID: 31653912
[TBL] [Abstract][Full Text] [Related]
23. The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents.
Dos Santos C; McDonald T; Ho YW; Liu H; Lin A; Forman SJ; Kuo YH; Bhatia R
Blood; 2013 Sep; 122(11):1900-13. PubMed ID: 23896410
[TBL] [Abstract][Full Text] [Related]
24. MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness-Promoting Chromatin Modifications Independent of p53.
Wienken M; Dickmanns A; Nemajerova A; Kramer D; Najafova Z; Weiss M; Karpiuk O; Kassem M; Zhang Y; Lozano G; Johnsen SA; Moll UM; Zhang X; Dobbelstein M
Mol Cell; 2016 Jan; 61(1):68-83. PubMed ID: 26748827
[TBL] [Abstract][Full Text] [Related]
25. A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1.
Loizou E; Banito A; Livshits G; Ho YJ; Koche RP; Sánchez-Rivera FJ; Mayle A; Chen CC; Kinalis S; Bagger FO; Kastenhuber ER; Durham BH; Lowe SW
Cancer Discov; 2019 Jul; 9(7):962-979. PubMed ID: 31068365
[TBL] [Abstract][Full Text] [Related]
26. Induction of the 5S RNP-Mdm2-p53 ribosomal stress pathway delays the initiation but fails to eradicate established murine acute myeloid leukemia.
Jaako P; Ugale A; Wahlestedt M; Velasco-Hernandez T; Cammenga J; Lindström MS; Bryder D
Leukemia; 2017 Jan; 31(1):213-221. PubMed ID: 27256803
[TBL] [Abstract][Full Text] [Related]
27. DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia.
Haines E; Nishida Y; Carr MI; Montoya RH; Ostermann LB; Zhang W; Zenke FT; Blaukat A; Andreeff M; Vassilev LT
Sci Rep; 2021 Jun; 11(1):12148. PubMed ID: 34108527
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders.
Kanavaros P; Stefanaki K; Rontogianni D; Darivianaki K; Vlychou M; Papadaki E; Eliopoulos G; Bakiri M; Matsouka C; Kakolyris S; Georgoulias V
Clin Exp Pathol; 1999; 47(5):231-8. PubMed ID: 10598372
[TBL] [Abstract][Full Text] [Related]
29. Low-frequency TP53 hotspot mutation contributes to chemoresistance through clonal expansion in acute myeloid leukemia.
Yan B; Chen Q; Xu J; Li W; Xu B; Qiu Y
Leukemia; 2020 Jul; 34(7):1816-1827. PubMed ID: 31988438
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of MN1 confers resistance to chemotherapy, accelerates leukemia onset, and suppresses p53 and Bim induction.
Pardee TS
PLoS One; 2012; 7(8):e43185. PubMed ID: 22905229
[TBL] [Abstract][Full Text] [Related]
31. Casein kinase 1α inhibits p53 downstream of MDM2‑mediated autophagy and apoptosis in acute myeloid leukemia.
Xu W; Huang Z; Gan Y; Chen R; Huang Y; Xue B; Jiang S; Yu Z; Yu K; Zhang S
Oncol Rep; 2020 Nov; 44(5):1895-1904. PubMed ID: 32901886
[TBL] [Abstract][Full Text] [Related]
32. Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy.
Pan R; Ruvolo V; Mu H; Leverson JD; Nichols G; Reed JC; Konopleva M; Andreeff M
Cancer Cell; 2017 Dec; 32(6):748-760.e6. PubMed ID: 29232553
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia.
Folkerts H; Hilgendorf S; Wierenga ATJ; Jaques J; Mulder AB; Coffer PJ; Schuringa JJ; Vellenga E
Cell Death Dis; 2017 Jul; 8(7):e2927. PubMed ID: 28703806
[TBL] [Abstract][Full Text] [Related]
34. Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling network.
Carter BZ; Mak PY; Chen Y; Mak DH; Mu H; Jacamo R; Ruvolo V; Arold ST; Ladbury JE; Burks JK; Kornblau S; Andreeff M
Oncotarget; 2016 Apr; 7(15):20054-67. PubMed ID: 26956049
[TBL] [Abstract][Full Text] [Related]
35. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation.
Ho JNHG; Schmidt D; Lowinus T; Ryoo J; Dopfer EP; Gonzalo Núñez N; Costa-Pereira S; Toffalori C; Punta M; Fetsch V; Wertheimer T; Rittmann MC; Braun LM; Follo M; Briere C; Vinnakota JM; Langenbach M; Koppers F; Shoumariyeh K; Engel H; Rückert T; Märklin M; Holzmayer S; Illert AL; Magon F; Andrieux G; Duquesne S; Pfeifer D; Staniek J; Rizzi M; Miething C; Köhler N; Duyster J; Menssen HD; Boerries M; Buescher JM; Cabezas-Wallscheid N; Blazar BR; Apostolova P; Vago L; Pearce EL; Becher B; Zeiser R
Blood; 2022 Sep; 140(10):1167-1181. PubMed ID: 35853161
[TBL] [Abstract][Full Text] [Related]
36. MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.
Howard TP; Arnoff TE; Song MR; Giacomelli AO; Wang X; Hong AL; Dharia NV; Wang S; Vazquez F; Pham MT; Morgan AM; Wachter F; Bird GH; Kugener G; Oberlick EM; Rees MG; Tiv HL; Hwang JH; Walsh KH; Cook A; Krill-Burger JM; Tsherniak A; Gokhale PC; Park PJ; Stegmaier K; Walensky LD; Hahn WC; Roberts CWM
Cancer Res; 2019 May; 79(9):2404-2414. PubMed ID: 30755442
[TBL] [Abstract][Full Text] [Related]
37. MDM2- and FLT3-inhibitors in the treatment of
Seipel K; Marques MAT; Sidler C; Mueller BU; Pabst T
Haematologica; 2018 Nov; 103(11):1862-1872. PubMed ID: 29976747
[TBL] [Abstract][Full Text] [Related]
38. Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia.
Piya S; Kornblau SM; Ruvolo VR; Mu H; Ruvolo PP; McQueen T; Davis RE; Hail N; Kantarjian H; Andreeff M; Borthakur G
Blood; 2016 Sep; 128(9):1260-9. PubMed ID: 27268264
[TBL] [Abstract][Full Text] [Related]
39. miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia.
Vu TT; Stölzel F; Wang KW; Röllig C; Tursky ML; Molloy TJ; Ma DD
Leukemia; 2021 Jul; 35(7):1933-1948. PubMed ID: 33262524
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy.
Cartel M; Mouchel PL; Gotanègre M; David L; Bertoli S; Mansat-De Mas V; Besson A; Sarry JE; Manenti S; Didier C
Leukemia; 2021 Feb; 35(2):417-432. PubMed ID: 32447346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
